Physician profile
Daryl C Wiley
NPI 1508859448
$4,014.19
in general payments reported to CMS, 2019-2025
33 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $261 · 2021: $570 · 2022: $924 · 2023: $440 · 2024: $613 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $768.14 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $722.68 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $380.35 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $339.61 | 2019-2024 | Farxiga |
| Pfizer INC. | $313.80 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $287.36 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.12 | 2021-2025 | |
| Lilly USA, LLC | $139.61 | 2019-2025 | Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $85.23 | 2024 | Qelbree |
| Astellas Pharma US INC | $81.32 | 2020-2024 | Veozah |
| Allergan, INC. | $79.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $75.74 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.27 | 2022-2024 | Jardiance |
| Abbott Laboratories | $45.27 | 2021-2024 | Eterna |
| Otsuka America Pharmaceutical, INC. | $45.12 | 2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $42.58 | 2024 | |
| Idorsia Pharmaceuticals US INC | $41.64 | 2023 | Quviviq |
| Amgen INC. | $35.57 | 2019 | |
| Ucb, INC. | $32.67 | 2025 | Briviact |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.76 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $26.73 | 2019 | |
| Corium, LLC | $18.84 | 2023 | Azstarys |
| Medtronic, INC. | $17.49 | 2024 | Minimed 780g |
| Dexcom, INC. | $16.60 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $16.36 | 2025 | Gardasil 9, Capvaxive |
| Avanir Pharmaceuticals, INC. | $15.43 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.86 | 2021 | |
| Genentech USA, INC. | $14.33 | 2020 | |
| Exact Sciences Corporation | $14.05 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.56 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $11.50 | 2021 | |
| Phathom Pharmaceuticals, INC. | $6.56 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.